Who
Herve Hoppenot
Director
Company insider
Files Form 4 as: Director, Maze Therapeutics; Director, Bicycle Therapeutics; Special Advisor to the CEO, Incyte.
In numbers
- Trades disclosed
- 104
- Buys
- 2
- Sells
- 4
- Bought
- $1.9M
- Sold
- $50.8M
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 13 Jan 2014
- Last trade
- 8 Jun 2026
- Last filed
- 10 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 8 Jun 2026filed 10 Jun 2026 | MAZE Maze Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,000 at $0.00 | filing |
| 8 Jun 2026filed 10 Jun 2026 | MAZE Maze Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | BCYC Bicycle TherapeuticsBiotechnology | SEC FORM 4 Code A | —3,032 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | BCYC Bicycle Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,065 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | BCYC Bicycle Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,065 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | BCYC Bicycle TherapeuticsBiotechnology | SEC FORM 4 Code A | —3,032 at $0.00 | filing |
| 8 Dec 2025filed 10 Dec 2025 | INCY IncyteLife-science tools | SEC FORM 4 Code F | $275K2,843 at $96.70 | filing |
| 10 Nov 2025filed 12 Nov 2025 | INCY IncyteLife-science tools | SEC FORM 4 Sold | $19.8M187,500 at $105.46 | filing |
| 6 Oct 2025filed 7 Oct 2025 | MAZE Maze Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —36,000 at $0.00 | filing |
| 8 Sep 2025filed 10 Sep 2025 | BCYC Bicycle Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 8 Sep 2025filed 10 Sep 2025 | BCYC Bicycle TherapeuticsBiotechnology | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 15 Jul 2025filed 16 Jul 2025 | INCY IncyteLife-science tools | SEC FORM 4 Code F | $322K4,713 at $68.25 | filing |
| 14 Jul 2025filed 16 Jul 2025 | INCY IncyteLife-science tools | SEC FORM 4 Code F | $347K4,961 at $69.98 | filing |
| 2 Jul 2025filed 7 Jul 2025 | INCY IncyteLife-science tools | SEC FORM 4 Code F | $2.9M42,769 at $68.17 | filing |
| 26 Jun 2025filed 30 Jun 2025 | INCY Incyteoption or derivative · Life-science tools | SEC FORM 4 Code A | —18,438 at $0.00 | filing |
| 26 Jun 2025filed 30 Jun 2025 | INCY Incyteoption or derivative · Life-science tools | SEC FORM 4 Code A | —18,050 at $0.00 | filing |
| 26 Jun 2025filed 30 Jun 2025 | INCY IncyteLife-science tools | SEC FORM 4 Code A | —6,016 at $0.00 | filing |
| 1 Apr 2025filed 3 Apr 2025 | INCY IncyteLife-science tools | SEC FORM 4 Code A | —66,899 at $0.00 | filing |
| 17 Jan 2025filed 22 Jan 2025 | INCY Incyteoption or derivative · Life-science tools | SEC FORM 4 Code A | —55,510 at $0.00 | filing |
| 15 Jul 2024filed 17 Jul 2024 | INCY Incyteoption or derivative · Life-science tools | SEC FORM 4 Code A | —61,189 at $0.00 | filing |
News
Comparing Madrigal Pharmaceuticals (NASDAQ:MDGL) and Incyte (NASDAQ:INCY)INCY · themarketsdaily.com · 20 Oct 2026
0 headlines in the last 90 days name Herve Hoppenot; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.